Banyu President Quits; Merck VP To Serve As Interim Boss (Japan)
This article was originally published in PharmAsia News
Executive Summary
Banyu Pharmaceutical Co. President Haruhiko Hirate will step down on Sept. 30. David Anstice, executive vice president of the firm's U.S. parent Merck & Co., will take over as interim chief until Hirate's successor is chosen. Hirate took office in January 2004 and, due partly to a lack of new products, failed to increase earnings. Sales totaled less than 200 billion yen in fiscal 2006, well below the target of more than 300 billion yen Hirate had set when he took over as president. (Click here for more - May Require Paid Subscription
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.